Vogl TJ, et al. - The purpose of this trial was to determine the overall (OS) and progression-free survival (PFS) for conventional transarterial chemoembolization (cTACE) alone and in combination with percutaneous thermal ablation in patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases (CRLM). cTACE was an effective treatment option in advanced non-resectable CRLM. An additional increase was achieved in the survival rates via chemoembolization followed by ablation. A triple combination of chemotherapeutics led to an improvement in the response to cTACE.